Esperion Therapeutics Inc (ESPR) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Esperion Therapeutics Inc stock (ESPR) is currently trading at $2.76. Esperion Therapeutics Inc PS ratio (Price-to-Sales) is 1.62. Analyst consensus price target for ESPR is $6.99. WallStSmart rates ESPR as Sell.
- ESPR PE ratio analysis and historical PE chart
- ESPR PS ratio (Price-to-Sales) history and trend
- ESPR intrinsic value — DCF, Graham Number, EPV models
- ESPR stock price prediction 2025 2026 2027 2028 2029 2030
- ESPR fair value vs current price
- ESPR insider transactions and insider buying
- Is ESPR undervalued or overvalued?
- Esperion Therapeutics Inc financial analysis — revenue, earnings, cash flow
- ESPR Piotroski F-Score and Altman Z-Score
- ESPR analyst price target and Smart Rating
Esperion Therapeutics Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Esperion Therapeutics Inc (ESPR) · 9 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in operating margin, price/sales, revenue growth. Concerns around peg ratio and return on equity. Mixed signals suggest waiting for clearer direction before acting.
Esperion Therapeutics Inc (ESPR) Key Strengths (4)
Keeps $51 of every $100 in revenue after operating costs
Revenue surging 143.70% year-over-year
Paying $1.62 for every $1 of annual revenue
60.98% held by institutions, strong professional interest
Supporting Valuation Data
Esperion Therapeutics Inc (ESPR) Areas to Watch (5)
PEG ratio is negative or unavailable
Company is destroying shareholder value
Company is losing money with a negative profit margin
Very expensive at 98.4x book value
Small-cap company with higher risk but more growth potential
Esperion Therapeutics Inc (ESPR) Detailed Analysis Report
Overall Assessment
This company scores 42/100 in our Smart Analysis, earning a D grade. Out of 9 metrics analyzed, 4 register as strengths (avg 9.0/10) while 5 fall into concern territory (avg 1.4/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Operating Margin, Revenue Growth, Price/Sales. Valuation metrics including Price/Sales (1.62) suggest the stock is attractively priced. Profitability is solid with Operating Margin at 50.60%. Growth metrics are encouraging with Revenue Growth at 143.70%.
The Bear Case
The primary concerns are PEG Ratio, Return on Equity, Profit Margin. Some valuation metrics including PEG Ratio (N/A), Price/Book (98.42) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -260.80%, Profit Margin at -5.63%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether PEG Ratio improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -260.80% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 143.70% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. PEG Ratio and Return on Equity are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
ESPR Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
ESPR's Price-to-Sales ratio of 1.62x trades at a deep discount to its historical average of 87.82x (12th percentile). The current valuation is 100% below its historical high of 2293.21x set in Jun 2020, and 108% above its historical low of 0.78x in May 2025. Over the past 12 months, the PS ratio has expanded from ~1.1x, reflecting growing market expectations outpacing revenue growth.
Compare ESPR with Competitors
Top DRUG MANUFACTURERS - SPECIALTY & GENERIC stocks by market cap
Compare any two stocks →WallStSmart Analysis Synopsis
Data-driven financial summary for Esperion Therapeutics Inc (ESPR) · HEALTHCARE › DRUG MANUFACTURERS - SPECIALTY & GENERIC
The Big Picture
Esperion Therapeutics Inc is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 403M with 144% growth year-over-year. The company is currently unprofitable, posting a -5.6% profit margin.
Key Findings
Revenue growing at 144% YoY, reaching 403M. This pace significantly outperforms most DRUG MANUFACTURERS - SPECIALTY & GENERIC peers.
Generating 45M in free cash flow and 45M in operating cash flow. Earnings are translating into actual cash generation.
The company is unprofitable with a -5.6% profit margin. The path to breakeven will be the key catalyst.
What to Watch Next
Growth sustainability: can Esperion Therapeutics Inc maintain 144%+ revenue growth, or will competition slow it down?
Sector dynamics: monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive moves, and regulatory changes that could impact Esperion Therapeutics Inc.
Bottom Line
Esperion Therapeutics Inc is a high-conviction growth story with revenue accelerating at 144% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin -5.6% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Esperion Therapeutics Inc(ESPR)
NASDAQ
HEALTHCARE
DRUG MANUFACTURERS - SPECIALTY...
USA
Esperion Therapeutics, Inc., a pharmaceutical company, develops and markets drugs for the treatment of patients with high low-density lipoprotein cholesterol in the United States and internationally. The company is headquartered in Ann Arbor, Michigan.